By
Autonomyo, which specializes in medical technology and was founded at EPFL, has raised €1.4 million from private and public investors and is now launching a crowdfunding campaign on Capital Cell to develop its home rehabilitation technology internationally. With its Skywalk product, a safety system combined with a smart exoskeleton and a digital therapy platform, Autonomyo is bringing robot-assisted rehabilitation from the clinic directly to patients' homes.
Every year, over 15 million people suffer a stroke. Half of them leave rehabilitation still unable to walk independently — not because recovery isn’t possible, but because intensive therapy is too costly and inaccessible.
Autonomyo, a Swiss MedTech spin-off from EPFL, is changing this reality with Skywalk, the world’s first intelligent safety frame that enables safe, assisted gait training at home. Combined with Autonomyo’s wearable exoskeleton and digital rehabilitation platform, it empowers patients to train daily, safely, and affordably — wherever they are.
After raising €1.4 million from public and private investors, Autonomyo is now opening its Capital Cell crowdfunding campaign to engage the community in its mission to give millions their independence back. “We’re building a future where effective rehabilitation is no longer limited to the hospital,” says Fabian Bischof, CEO and co-founder. “Skywalk lets patients train safely at home — it’s affordable, empowering, and life-changing.”
The company has already completed successful clinical trials at CHUV (University Hospital of Lausanne) and is preparing CE certification and FDA readiness for 2025. Now, through crowdfunding, Autonomyo aims to accelerate the industrialization of its Skywalk and Exoskeleton V3, expand its digital training content, and bring the solution to thousands of homes worldwide.
To take part in the movement in order to help millions walk again, you can join the campaign here: https://capitalcell.com/en/campaign/autonomyo/
-1.png "Gaza Fund (1)-1")
